Matthew K. Fust
CIK: 0001397266
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (31 total)
- Sep 1, 2026CRNX
Crinetics Pharmaceuticals, Inc.
Disposition(D)Direct22.8K shares at avg. $85.00$1.9M - Sep 1, 2026CRNX
Crinetics Pharmaceuticals, Inc.
Disposition(D)Direct5.9K shares at avg. $85.00$504K - Jun 18, 2026CRNX
Crinetics Pharmaceuticals, Inc.
Award(A)Direct5.9K shares- - Jun 9, 2026ATRA
Atara Biotherapeutics, Inc.
Award(A)Direct12K shares- - May 27, 2026NMRA
Neumora Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
80K shares- - May 14, 2026RARE
Ultragenyx Pharmaceutical Inc.
Award(A)Direct7.8K shares- - Sep 26, 2025CRNX
Crinetics Pharmaceuticals, Inc.
Exercise(M)Direct10K shares at avg. $1.91$19K - Sep 26, 2025CRNX
Crinetics Pharmaceuticals, Inc.
Sale(S)Direct16K shares at avg. $44.75$716K - Jun 11, 2025CRNX
Crinetics Pharmaceuticals, Inc.
Award(A)Direct6.9K shares- - Jun 10, 2025ATRA
Atara Biotherapeutics, Inc.
Award(A)Direct7.8K shares- - May 28, 2025NMRA
Neumora Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
28.6K shares- - May 28, 2025NMRA
Neumora Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
85.6K shares- - May 28, 2025NMRA
Neumora Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
27.8K shares- - May 28, 2025NMRA
Neumora Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
85.6K shares- - May 28, 2025NMRA
Neumora Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
27.8K shares- - May 28, 2025NMRA
Neumora Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
28.6K shares- - May 28, 2025NMRA
Neumora Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
80K shares- - May 15, 2025RARE
Ultragenyx Pharmaceutical Inc.
Award(A)Direct5.7K shares- - Feb 13, 2025NMRA
Neumora Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
28.6K shares- - Feb 13, 2025NMRA
Neumora Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
85.6K shares- - Feb 13, 2025NMRA
Neumora Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
27.8K shares- - Feb 13, 2025NMRA
Neumora Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
28.6K shares- - Feb 13, 2025NMRA
Neumora Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
27.8K shares- - Feb 13, 2025NMRA
Neumora Therapeutics, Inc.
Disposition(D)DirectStock Option (Right to Buy)
85.6K shares- - Oct 18, 2024NMRA
Neumora Therapeutics, Inc.
Exercise(M)Direct6.2K shares at avg. $8.79$55K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 1, 2026 |  CRNX Crinetics Pharmaceuticals, Inc. | Disposition(D) | 22,836 | $85.00 | $1,941,060 | Direct |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Disposition(D) | 5,925 | $85.00 | $503,625 | Direct |
| Jun 18, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Award(A) | 5,925 | - | $0 | Direct |
| Jun 9, 2026 |  ATRA Atara Biotherapeutics, Inc. | Award(A) | 12,000 | - | $0 | Direct |
| May 27, 2026 |  NMRA Neumora Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 80,000 | - | - | Direct |
| May 14, 2026 |  RARE Ultragenyx Pharmaceutical Inc. | Award(A) | 7,751 | - | $0 | Direct |
| Sep 26, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | Exercise(M) | 10,000 | $1.91 | $19,100 | Direct |
| Sep 26, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | Sale(S) | 16,000 | $44.75 | $716,000 | Direct |
| Jun 11, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | Award(A) | 6,900 | - | - | Direct |
| Jun 10, 2025 | ATRA Atara Biotherapeutics, Inc. | Award(A) | 7,828 | - | - | Direct |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 28,571 | - | - | Direct |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 85,586 | - | - | Direct |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 27,802 | - | - | Direct |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 85,586 | - | - | Direct |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 27,802 | - | - | Direct |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 28,571 | - | - | Direct |
| May 28, 2025 | NMRA Neumora Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 80,000 | - | - | Direct |
| May 15, 2025 | RARE Ultragenyx Pharmaceutical Inc. | Award(A) | 5,740 | - | - | Direct |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 28,571 | - | - | Direct |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 85,586 | - | - | Direct |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 27,802 | - | - | Direct |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 28,571 | - | - | Direct |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 27,802 | - | - | Direct |
| Feb 13, 2025 | NMRA Neumora Therapeutics, Inc. | Disposition(D) Stock Option (Right to Buy) | 85,586 | - | - | Direct |
| Oct 18, 2024 | NMRA Neumora Therapeutics, Inc. | Exercise(M) | 6,205 | $8.79 | $54,542 | Direct |
1-25 of 31 transactions
About Fust Matthew K
Fust Matthew K (SEC CIK 0001397266) files insider reports with the SEC as Director of Electra Therapeutics, Inc. (ETRA), Director of Crinetics Pharmaceuticals, Inc. (CRNX) and Director of Atara Biotherapeutics, Inc. (ATRA). Signal8 also holds filings tied to 2 other companies.
Signal8 holds 13 ownership filings by Fust Matthew K (1 Form 3, 12 Form 4), filed between Oct 18, 2024 and Sep 18, 2026. Those filings report 31 transactions, from Oct 17, 2024 to Sep 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Fust Matthew K's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Fust Matthew K
- Sep 1, 2026: Disposition to issuer transactions of CRNX shares (2 lines, Form 4, code D).
- Jun 18, 2026: Grant or award of CRNX shares (Form 4, code A).
- Jun 9, 2026: Grant or award of ATRA shares (Form 4, code A).
- May 27, 2026: Grant or award of NMRA derivative securities (Form 4, code A).
- May 14, 2026: Grant or award of RARE shares (Form 4, code A).
Other insiders filing for Electra Therapeutics, Inc. (ETRA)
- GORDON CARL L, Director
- ORBIMED ADVISORS LLC, Director
- Westlake BioPartners Fund I, L.P., 10% Owner
- Koe Gary S., Chief Technical Officer
- Stagliano Nancy, Director
- Parry Graham, Principal Accounting Officer